1.5 T MR-Linac上胰腺肿瘤MR引导SBRT的治疗计划:全球共识协议
由十三家中心组成联盟,针对1.5 T MR-Linac上胰腺肿瘤MR引导SBRT制定共识计划协议;经三阶段计划演练, benchmarking阶段GTV D99%范围病例1为36.8-53.7 Gy、病例2为22.6-35.5 Gy,最终共识阶段病例1为48.2-50.9 Gy、病例2为33.5-36.0 Gy,并减少估计治疗时间变异。
要点
- 十三家中心参与三阶段计划演练后达成1.5 T MR-Linac胰腺MR引导SBRT共识计划协议。
- 共识协议使GTV D99%范围病例1为48.2-50.9 Gy、病例2为33.5-36.0 Gy,较 benchmarking阶段 harmonization。
- 该协议可为计划在MR-Linac系统上治疗胰腺肿瘤的中心提供起始参考。
核心结论
- 已制定1.5 T MR-Linac上胰腺肿瘤MR引导SBRT治疗计划的全球共识协议。
- 该协议可协调当前临床实践中的巨大差异,并为计划在MR-Linac系统上治疗胰腺肿瘤的中心提供起始参考。
研究设计与样本
- 由十三家中心组成联盟,各中心均治疗1.5 T MR-Linac上的胰腺肿瘤。
- 进行分阶段计划演练:各中心针对两例胰腺癌病例迭代创建治疗计划,每阶段后开会确定下一阶段指令,三阶段后达成共识协议。
主要发现
- 基准阶段(I期)各中心SBRT协议间差异显著:病例1的GTV D99%范围为36.8-53.7 Gy,病例2为22.6-35.5 Gy。
- II期采用相同基本剂量学目标、约束和计划边界后实现高度协调:病例1的GTV D99%范围为47.9-53.6 Gy,病例2为33.9-36.6 Gy。
- III期将最终共识协议制定为治疗计划系统模板并再次用于计划,病例1的GTV D99%范围为48.2-50.9 Gy,病例2为33.5-36.0 Gy,且估计治疗交付时间变异减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Treatment planning for MR-guided stereotactic body radiotherapy (SBRT) for pancreatic tumors can be challenging, leading to a wide variation of protocols and practices. This study aimed to harmonize treatment planning by developing a consensus planning protocol for MR-guided pancreas SBRT on a 1.5 T MR-Linac. MATERIALS AND METHODS: A consortium was founded of thirteen centers that treat pancreatic tumors on a 1.5 T MR-Linac. A phased planning exercise was conducted in which centers iteratively created treatment plans for two cases of pancreatic cancer. Each phase was followed by a meeting where the instructions for the next phase were determined. After three phases, a consensus protocol was reached. RESULTS: In the benchmarking phase (phase I), substantial variation between the SBRT protocols became apparent (for example, the gross tumor volume (GTV) D99% ranged between 36.8 - 53.7 Gy for case 1, 22.6 - 35.5 Gy for case 2). The next phase involved planning according to the same basic dosimetric objectives, constraints, and planning margins (phase II), which led to a large degree of harmonization (GTV D99% range: 47.9-53.6 Gy for case 1, 33.9-36.6 Gy for case 2). In phase III, the final consensus protocol was formulated in a treatment planning system template and again used for treatment planning. This not only resulted in further dosimetric harmonization (GTV D99% range: 48.2-50.9 Gy for case 1, 33.5-36.0 Gy for case 2) but also in less variation of estimated treatment delivery times. CONCLUSION: A global consensus protocol has been developed for treatment planning for MR-guided pancreatic SBRT on a 1.5 T MR-Linac. Aside from harmonizing the large variation in the current clinical practice, this protocol can provide a starting point for centers that are planning to treat pancreatic tumors on MR-Linac systems.
引用
- Grimbergen G, Eijkelenkamp H, Snoeren LMW, et al. Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol. Clin Transl Radiat Oncol. 2024. PMID: 38831754. doi:10.1016/j.ctro.2024.100797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。